Forte Biosciences (FBRX) Accumulated Expenses (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Accumulated Expenses data on file, last reported at $10.6 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $10.6 million, up 745.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.6 million (up 745.04% YoY), and the FY2025 annual result was $10.8 million, up 593.87% from the prior year.
• Accumulated Expenses declined to $10.6 million in Q1 2026 per FBRX's latest filing, from $10.8 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $10.8 million in Q4 2025 and troughed at $454000.0 in Q2 2022.
• A 5-year average of $3.0 million and a median of $1.6 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses tumbled 77.22% in 2022, then jumped 745.04% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $2.0 million in 2022, then slumped by 53.26% to $947000.0 in 2023, then soared by 63.78% to $1.6 million in 2024, then jumped by 593.87% to $10.8 million in 2025, then retreated by 1.85% to $10.6 million in 2026.
• Business Quant data shows FBRX's Accumulated Expenses at $10.6 million in Q1 2026, $10.8 million in Q4 2025, and $7.5 million in Q3 2025.